Pemphigus Vulgaris

Obtain a biopsy from an active lesion for routine histopathology and a separate perilesional specimen for immunopathologic assessment when PV is suspected clinically. Pemphigus disorders are defined by intraepidermal split formation, whereas other autoimmune bullous diseases blister at the basement-membrane zone; this distinction redirects both serologic interpretation and treatment planning. ScienceDirect+1ScienceDirectDiagnosis and management of pemphigus: Recommendations of an international panel of experts - ScienceDirectPubMedDiagnosis and clinical features of pemphigus vulgaris - PubMed

Do not treat persistent oral erosions or erosive skin disease as PV on morphology alone. The diagnostic branch includes PV, pemphigus foliaceus, drug-induced pemphigus, paraneoplastic pemphigus, and non-pemphigus autoimmune blistering disease; the level of split formation and autoantibody pattern determine the specific diagnosis. ScienceDirect+1ScienceDirectDiagnosis and management of pemphigus: Recommendations of an international panel of experts - ScienceDirectPubMedDiagnosis and clinical features of pemphigus vulgaris - PubMed

If erosions are extensive, involve multiple mucosal sites, or precede systemic treatment, document baseline extent and functional consequences, particularly oral intake. Clinical assessment remains central because pemphigus diagnosis is based on the observed pattern of erosions, epidermal loss, and blisters in conjunction with confirmatory testing. BMJBMJPemphigus - Symptoms, diagnosis and treatment - BMJ Best Practice

Assess oral disease at presentation for painful erosions that limit hydration, nutrition, medication administration, or oral hygiene. Mucocutaneous PV requires treatment planning that addresses both mucosal and skin activity rather than judging severity from cutaneous blisters alone. ScienceDirect+1ScienceDirectWorld Workshop on Oral Medicine VI: a systematic review of the treatment of mucocutaneous pemphigus vulgaris - ScienceDirectWileyOral Pemphigus Vulgaris Treatment with Corticosteroids and ...

Ask specifically about dysphonia, odynophagia, dysphagia, throat pain, cough, or dyspnea. Laryngeal involvement occurs in PV, and a clinical prediction model has been developed for deep laryngeal involvement; concerning upper-airway symptoms should prompt direct laryngeal assessment rather than observation alone. JAMAJAMAPredicting Laryngeal Involvement in Pemphigus Vulgaris Using a ...

When oral intake is impaired, address hydration and nutritional support concurrently with disease-directed immunosuppression. Referral to clinicians experienced in mucosal autoimmune blistering disease is particularly important when oral, pharyngeal, esophageal, or laryngeal involvement is suspected. ScienceDirect+1ScienceDirectWorld Workshop on Oral Medicine VI: a systematic review of the treatment of mucocutaneous pemphigus vulgaris - ScienceDirectJAMAPredicting Laryngeal Involvement in Pemphigus Vulgaris Using a ...

For moderate-to-severe PV, consider rituximab as a first-line systemic option, combined with the corticosteroid strategy needed for disease control. International expert consensus includes intravenous CD20 inhibitors as first-line therapy for moderate-to-severe pemphigus, and rituximab has demonstrated a steroid-sparing effect in PV. ScienceDirect+1ScienceDirectDiagnosis and management of pemphigus: Recommendations of an international panel of experts - ScienceDirectJAMAOptimizing Pemphigus Management With Rituximab and Short-Term ...

Systemic corticosteroids remain an induction option; cited guideline dosing is 1.0-1.5 mg/kg/day of systemic corticosteroid therapy for initial PV/PF treatment. WileyWileyS2k guidelines for the treatment of pemphigus vulgaris/foliaceus and ... A separate oral PV treatment protocol used prednisolone 1 mg/kg/day initially, with reassessment after 4-6 weeks. WileyWileyOral Pemphigus Vulgaris Treatment with Corticosteroids and ... Use the lowest regimen that achieves control and taper only after disease control, because consensus guidance addresses maintenance and tapering in remission rather than endorsing an arbitrary early taper. ScienceDirectScienceDirectDiagnosis and management of pemphigus: Recommendations of an international panel of experts - ScienceDirect

For patients in whom rituximab is unavailable, contraindicated, or insufficiently effective, conventional immunosuppressive adjuncts are used as steroid-sparing therapy. Mycophenolate mofetil has been used at 2-3 g/day in two divided doses in PV; comparative discussions note a tradeoff between lower hepatotoxicity and differing corticosteroid-sparing performance versus azathioprine. ScienceDirectScienceDirectA systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus - ScienceDirect

At each follow-up, determine whether new erosions or blisters are appearing, whether prior lesions are healing, and whether mucosal symptoms are improving enough to restore oral intake and function. Consensus recommendations specifically address maintenance therapy and medication tapering in remission, making clinical disease control the central trigger for de-escalation. ScienceDirectScienceDirectDiagnosis and management of pemphigus: Recommendations of an international panel of experts - ScienceDirect

Counsel patients receiving rituximab that relapse remains clinically relevant after initial response. Reported 12-month relapse-free survival rates in PV rituximab studies ranged from 40% to 80%, supporting planned surveillance rather than assuming a single infusion cycle produces durable remission in every patient. BMJBMJthe OBIRINS study protocol, a double-blind randomised controlled trial

In one newly diagnosed pemphigus cohort, rituximab was administered as 1,000 mg intravenously on days 0 and 14, followed by a 500-mg infusion; this regimen should be interpreted as a studied approach rather than a universal schedule. JAMAJAMAFactors Associated With Short-term Relapse in Patients With ... Choose maintenance or retreatment strategies in coordination with pemphigus expertise and according to disease recurrence, prior response, and treatment toxicity. ScienceDirectScienceDirectDiagnosis and management of pemphigus: Recommendations of an international panel of experts - ScienceDirect

Do not classify every erosive mucosal disorder as PV. Pemphigus variants are distinguished by the level of intraepidermal split formation, while pemphigoid-spectrum disorders blister at the basement membrane zone; biopsy-directed classification should precede long-term immunosuppression. PubMed+1PubMedDiagnosis and clinical features of pemphigus vulgaris - PubMedScienceDirectDiagnosis and management of pemphigus: Recommendations of an international panel of experts - ScienceDirect

Do not delay laryngeal assessment because oral disease appears mild. PV can involve the larynx, and symptoms suggesting deep laryngeal disease require targeted assessment. JAMAJAMAPredicting Laryngeal Involvement in Pemphigus Vulgaris Using a ...

Do not leave patients on prolonged systemic corticosteroid therapy without an explicit steroid-sparing plan when disease severity warrants rituximab or another adjunct. Rituximab's demonstrated steroid-sparing effect and its first-line role in moderate-to-severe disease make early treatment selection clinically important. JAMA+1JAMAOptimizing Pemphigus Management With Rituximab and Short-Term ...ScienceDirectDiagnosis and management of pemphigus: Recommendations of an international panel of experts - ScienceDirect